Next Article in Journal
Identification, Classification and Screening for γ-Amino-butyric Acid Production in Lactic Acid Bacteria from Cambodian Fermented Foods
Previous Article in Journal
The Plasma Factor XIII Heterotetrameric Complex Structure: Unexpected Unequal Pairing within a Symmetric Complex
Open AccessArticle

Salivary Protein Panel to Diagnose Systolic Heart Failure

1
Saliva and Liquid Biopsy Translational Research Team, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland 4059, Australia
2
School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland 4059, Australia
3
Department of Cardiology, Mater Adult Hospital, Brisbane, Queensland 4101, Australia
4
Cardiology Department, Royal Brisbane and Women’s Hospital and University of Queensland School of Medicine, Brisbane, Queensland 4029, Australia
*
Author to whom correspondence should be addressed.
Biomolecules 2019, 9(12), 766; https://doi.org/10.3390/biom9120766
Received: 22 October 2019 / Revised: 18 November 2019 / Accepted: 19 November 2019 / Published: 22 November 2019
Screening for systolic heart failure (SHF) has been problematic. Heart failure management guidelines suggest screening for structural heart disease and SHF prevention strategies should be a top priority. We developed a multi-protein biomarker panel using saliva as a diagnostic medium to discriminate SHF patients and healthy controls. We collected saliva samples from healthy controls (n = 88) and from SHF patients (n = 100). We developed enzyme linked immunosorbent assays to quantify three specific proteins/peptide (Kallikrein-1, Protein S100-A7, and Cathelicidin antimicrobial peptide) in saliva samples. The analytical and clinical performances and predictive value of the proteins were evaluated. The analytical performances of the immunoassays were all within acceptable analytical ranges. The multi-protein panel was able to significantly (p < 0.001) discriminate saliva samples collected from patients with SHF from controls. The multi-protein panel demonstrated good performance with an overall diagnostic accuracy of 81.6% (sensitivity of 79.2% and specificity of 85.7%) when distinguishing SHF patients from healthy individuals. In conclusion, we have developed immunoassays to measure the salivary concentrations of three proteins combined as a panel to accurately distinguish SHF patients from healthy controls. While this requires confirmation in larger cohorts, our findings suggest that this three-protein panel has the potential to be used as a biomarker for early detection of SHF. View Full-Text
Keywords: systolic heart failure; cardiovascular diseases; saliva; biomarker; diagnosis; screen; prognosis systolic heart failure; cardiovascular diseases; saliva; biomarker; diagnosis; screen; prognosis
Show Figures

Graphical abstract

MDPI and ACS Style

Zhang, X.; Broszczak, D.; Kostner, K.; Guppy-Coles, K.B.; Atherton, J.J.; Punyadeera, C. Salivary Protein Panel to Diagnose Systolic Heart Failure. Biomolecules 2019, 9, 766.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop